View Post

Real-World Outcomes Favor Standard Care in HER2-Positive Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Gregory Laub From: medpagetoday.com After the results of CLEOPATRA, taxane chemotherapy with dual anti-HER2-blocker therapy Herceptin [trastuzumab]/Perjeta [pertuzumab] became the standard of care for HER2-positive metastatic breast cancer. With this study, we were looking to see how many patients in the real world received that regimen as a first-line standard-of-care therapy, which we defined as “1LSOC” compared to an …